Drawing for Serial No. 79191976

USPTO serial 79191976

Serial No. 79191976

Reviewed by CopyMark Law Group

Reg. 5158531Status 709
Filing date
Status date
Registration date
Mar 14, 2017
Examiner
STIGLITZ, SUSAN R
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79191976?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; anti-fungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 20, 2024INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jun 27, 2024INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jun 27, 2024INPCINVALIDATION PROCESSED—
Jun 14, 2024INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 29, 2023C71TCANCELLED SECTION 71—
Mar 14, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 8, 2017FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 22, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 22, 2017FIMPFINAL DISPOSITION PROCESSED—
Jun 14, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 14, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 27, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 27, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 7, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 21, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 11, 2016RFNTREFUSAL PROCESSED BY IB—
Nov 4, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 4, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 4, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 26, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 26, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 21, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 21, 2016RFRRREFUSAL PROCESSED BY MPU—
Oct 5, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 4, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 1, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 27, 2016DOCKASSIGNED TO EXAMINER—
Sep 27, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 26, 2016LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Sep 22, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance